Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2011 Mar;29(3):214-9. doi: 10.3109/07357907.2010.550663.

Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma.

Author information

1
Division of Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA. anne.beaven@duke.edu

Abstract

This study combined infusional mitoxantrone with bolus melphalan as a transplant preparative regimen for multiple myeloma. Mitoxantrone was infused over 6 hr on days 6 and 5. Melphalan was given as a 15 min bolus on day 1 followed by autologous transplant on day 0. Thirty-five patients were enrolled; 57% of enrollees had received ≥ 2 prior treatments. The median overall survival was 5 years and 8 months, with 37% of the subjects alive >7 years posttransplantation. Myelosuppression and mucositis were the most frequent adverse events. This regimen is well tolerated and the survival compares well to other transplant trials.

PMID:
21314330
DOI:
10.3109/07357907.2010.550663
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center